MPL Mutational Analysis
Approximately 50% of essential thrombocythemia (ET) and primary myelofibrosis (PMF) have the p.V617F activating mutation in JAK2; a smaller proportion of ET cases (5-10%) have an activating mutation in codon 515 of the thrombopoietin receptor, MPL. This assay can also be used to track levels of residual disease in MPL-mutated tumors following treatment.
PCR-based pyrosequencing of DNA is performed to examine mutational status of codon 515 of MPL. The level of mutated/unmutated PCR product is reported.
Tumor clone must comprise at least 5% of the cells in the sample for accurate assessment. Levels are quantitative with approximately 5-10% variability.
- 10 ml peripheral blood, 2-5mL bone marrow aspirate, 5ug purified DNA
- 4-10 unstained tissue sections on glass slides along with 1 H&E-stained section.
Please provide a copy of the corresponding pathology report.
Additional charges may apply for tissue extraction.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.